745 related articles for article (PubMed ID: 19014832)
1. Raltegravir: the first HIV integrase inhibitor.
Cocohoba J; Dong BJ
Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
[TBL] [Abstract][Full Text] [Related]
2. Role of raltegravir in HIV-1 management.
Rokas KE; Bookstaver PB; Shamroe CL; Sutton SS; Millisor VE; Bryant JE; Weissman SB
Ann Pharmacother; 2012 Apr; 46(4):578-89. PubMed ID: 22496475
[TBL] [Abstract][Full Text] [Related]
3. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
Summa V; Petrocchi A; Bonelli F; Crescenzi B; Donghi M; Ferrara M; Fiore F; Gardelli C; Gonzalez Paz O; Hazuda DJ; Jones P; Kinzel O; Laufer R; Monteagudo E; Muraglia E; Nizi E; Orvieto F; Pace P; Pescatore G; Scarpelli R; Stillmock K; Witmer MV; Rowley M
J Med Chem; 2008 Sep; 51(18):5843-55. PubMed ID: 18763751
[TBL] [Abstract][Full Text] [Related]
4. Raltegravir: the first HIV type 1 integrase inhibitor.
Hicks C; Gulick RM
Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
[TBL] [Abstract][Full Text] [Related]
5. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
[TBL] [Abstract][Full Text] [Related]
6. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
Nguyen BY; Isaacs RD; Teppler H; Leavitt RY; Sklar P; Iwamoto M; Wenning LA; Miller MD; Chen J; Kemp R; Xu W; Fromtling RA; Vacca JP; Young SD; Rowley M; Lower MW; Gottesdiener KM; Hazuda DJ
Ann N Y Acad Sci; 2011 Mar; 1222():83-9. PubMed ID: 21434946
[TBL] [Abstract][Full Text] [Related]
7. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
Burger DM
Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
[TBL] [Abstract][Full Text] [Related]
8. Raltegravir with optimized background therapy for resistant HIV-1 infection.
Steigbigel RT; Cooper DA; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Nguyen BY; Teppler H;
N Engl J Med; 2008 Jul; 359(4):339-54. PubMed ID: 18650512
[TBL] [Abstract][Full Text] [Related]
9. Raltegravir, an HIV-1 integrase inhibitor for HIV infection.
Cabrera C
Curr Opin Investig Drugs; 2008 Aug; 9(8):885-98. PubMed ID: 18666037
[TBL] [Abstract][Full Text] [Related]
10. Novel integrase inhibitors for HIV.
Prada N; Markowitz M
Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
[TBL] [Abstract][Full Text] [Related]
11. Integrase inhibitors in the treatment of HIV-1 infection.
Powderly WG
J Antimicrob Chemother; 2010 Dec; 65(12):2485-8. PubMed ID: 20852268
[TBL] [Abstract][Full Text] [Related]
12. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
Cooper DA; Steigbigel RT; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Teppler H; Nguyen BY;
N Engl J Med; 2008 Jul; 359(4):355-65. PubMed ID: 18650513
[TBL] [Abstract][Full Text] [Related]
13. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
14. GSK-1349572, a novel integrase inhibitor for the treatment of HIV infection.
Vandekerckhove L
Curr Opin Investig Drugs; 2010 Feb; 11(2):203-12. PubMed ID: 20112170
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.
Brainard DM; Wenning LA; Stone JA; Wagner JA; Iwamoto M
J Clin Pharmacol; 2011 Oct; 51(10):1376-402. PubMed ID: 21209233
[TBL] [Abstract][Full Text] [Related]
16. Raltegravir as antiretroviral therapy in HIV/AIDS.
Sharma M; Walmsley SL
Expert Opin Pharmacother; 2014 Feb; 15(3):395-405. PubMed ID: 24304203
[TBL] [Abstract][Full Text] [Related]
17. Raltegravir: the first in a new class of integrase inhibitors for the treatment of HIV.
Sayana S; Khanlou H
Expert Rev Anti Infect Ther; 2008 Aug; 6(4):419-26. PubMed ID: 18662108
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
19. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
20. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.
Buzón MJ; Marfil S; Puertas MC; Garcia E; Clotet B; Ruiz L; Blanco J; Martinez-Picado J; Cabrera C
Antivir Ther; 2008; 13(7):881-93. PubMed ID: 19043922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
